Provided by Tiger Trade Technology Pte. Ltd.

REVVITY INC

128.67
-0.1300-0.10%
Pre-market: 128.66-0.0100-0.01%09:03 EDT
Volume:1.63M
Turnover:208.85M
Market Cap:14.39B
PE:61.44
High:128.82
Open:127.34
Low:125.46
Close:128.80
52wk High:130.07
52wk Low:81.22
Shares:111.80M
Float Shares:102.00M
Volume Ratio:1.13
T/O Rate:1.60%
Dividend:0.28
Dividend Rate:0.22%
EPS(TTM):2.09
EPS(LYR):2.07
ROE:3.21%
ROA:2.37%
PB:1.99
PE(LYR):62.20

Loading ...

Revvity Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
May 09

Revvity releases transcript of first-quarter 2026 earnings call

Reuters
·
May 08

Revvity Is Maintained at Equal-Weight by Barclays

Dow Jones
·
May 08

Revvity Inc. Stock Climbs 7.4%, Outperforms Peers

Dow Jones
·
May 07

Revvity Inc. Stock Advances 6.7%, Outperforms Peers

Dow Jones
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

BUZZ-Revvity rises after first-quarter profit beat

Reuters
·
May 05

Stock Track | Revvity Soars 6.24% Intraday on Strong Q1 Earnings Beat and Strategic China Business Divestiture

Stock Track
·
May 05

Revvity Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Revvity Exec Says Seasonal Uptick Seen From Q1 to Q2; Margins Expected to Rise to About 29% in Q3 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says China Diagnostics Demand, Pricing Hit by Policy Headwinds - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Plans to Remain Prudent With Its Forward-Looking Assumptions - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co's Immuno-Diagnostics Business Declined in the Low Single Digits Organically in Q1 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Expects Q2 Organic Growth to Be in the Range of 2% to 3% - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Exepcts a Continuation, IF Not Acceleration, of Life Sciences Performance in Chine Through 2026 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Saw Positive Growth From Pharma and Academic Customer for the First Time Since Q2 2023 - Conf Call

THOMSON REUTERS
·
May 05

Revvity trims annual profit, sales forecast to exclude China immunodiagnostics unit

Reuters
·
May 05

GUIDANCE: (RVTY) Revvity Expects 2026 Adjusted EPS Range $5.20-$5.30, vs. FactSet Est of $5.39

MT Newswires Live
·
May 05

GUIDANCE: (RVTY) Revvity Expects 2026 Pro Forma Revenue Range $2.81B-$2.84B

MT Newswires Live
·
May 05

Revvity Q1 Adj. EPS $1.06 Beats $1.02 Estimate, Sales $711.118M Beat $705.134M Estimate.

Benzinga Earnings
·
May 05